Articles
March 6, 2020
IWD 2020: Alnylam Women Reflect on Personal Experiences & Inspiration
We asked Alnylam women from across the globe to share to share a personal experience or inspiration that has shaped how they view gender and science at work.
Read More ›
February 25, 2020
Advocacy for Impact Grants: Updates from the Field
Learn about how patient organizations who received 2018-2019 Alnylam Advocacy for Impact Grants have been putting those funds to work.
Read More ›
February 19, 2020
Making Strides in Gender Parity
Alnylam ranked #3 in gender parity and #1 in fair representation for Women of Color (WOC) in Executive and Board Leadership among the top 25 employers in MA.
Read More ›
January 9, 2020
Expressing the Puzzling Challenges of hATTR Amyloidosis Through Art
We recently spoke with Peggy and her life partner Dan, who is living with hATTR amyloidosis, about their submission, At the Coffee Shop.
Read More ›
December 12, 2019
Building Bridges to Support Patients’ Care
Supporting patients and their caregivers by facilitating access to innovative treatments is at the core of our Patient Access Philosophy.
Read More ›
December 4, 2019
Guest Post: Partnering to Educate the African American Community About hATTR Amyloidosis
One of our areas of focus at Black Health Matters is education about the importance of knowing one’s family health history.
Read More ›
November 18, 2019
Alnylam Named a Boston Globe Top Place to Work for 5th Year in a Row
We're thrilled to be named a Top Places to Work for 2019 by The Boston Globe in the "Large Employer" category, marking our fifth year in a row on the list.
Read More ›
November 5, 2019
A Truly Special Place for Science
Recently, our company was named Science Magazine’s Top Employer for 2019 – a significant achievement in the scientific community and a true milestone...
Read More ›
October 25, 2019
Alnylam Named #1 Biopharma Employer by Science Magazine
Alnylam has been named the #1 science employer in biopharma for 2019 by Science Magazine and Science Careers. This is our first appearance on the list.
Read More ›